Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine
therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone-…

Background The efficacy and safety of treatment with cabozantinib in combination with
nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma …

Background In this retrospective analysis, we explored the prognostic and predictive value
of the systemic immune-inflammation index (SII), based on lymphocyte, neutrophil, and …

Background Immune checkpoint inhibitors (ICIs) represent the standard of care as first- or
second-line treatment in patients with renal cell carcinoma (RCC). Proton pump inhibitors (PPIs…

Invasive breast cancer is the most common malignancy in women. Its most common site of
metastasis is represented by the lymph nodes of axilla, and the sentinel lymph node (SLN) is …

308 Background: First-line NIVO+CABO met primary and secondary efficacy endpoints by
improving progression-free survival (PFS; HR 0.51, P < 0.0001), overall survival (OS; HR 0.60, …

Perivascular epithelioid cell tumors (PEComas) are rare tumors driven by tuberous sclerosis
complex gene mutations causing up-regulation of mTOR. We report the outcome of ten …

Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC)
patients achieve a long-term benefit from immunotherapy. Moreover, the identification of …

Background Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm, described in several
locations in the body. It is classified as intermediate malignant potential with low risk of …

Background Treatment options for penile squamous cell carcinoma are limited. We sought
to investigate clinical outcomes and safety profiles of patients with penile squamous cell …